Achieved revenues of $13.7 million in the orthofixation business, a 44 percent increase over the third quarter of 2014.

Achieved revenues of $9.8 million in the BGS and general orthopedic business, a 6 percent increase over the third quarter of 2014.

Achieved revenues of $6 million in the dental business, a 20 percent increase over the third quarter of 2014.

Achieved revenues of $5.5 million in the international business, a 13 percent increase on a constant currency basis over the third quarter of 2014.

Worldwide revenues were $66.5 million for the third quarter of 2015 compared to revenues of $65.2 million for the third quarter of 2014. Domestic revenues were $61 million for the third quarter of 2015 compared to revenues of $59.7 million for the third quarter of 2014. International revenues were $5.5 million for the third quarter of 2015, which were comparable to the third quarter of 2014. On a constant currency basis, international revenues for the third quarter of 2015 increased 13 percent compared to the third quarter of 2014.

“Our results for the third quarter were mixed with revenues coming in below our guidance and earnings meeting our guidance,” said Brian K. Hutchison, president and chief executive officer. “While the third quarter is traditionally impacted by seasonal trends in surgery, the impact this year was greater than we anticipated. Our revenue shortfall was largely due to lower than expected growth in our direct distribution business as well as declines in certain segments of the commercial business, offset by increased traction in our international business. Due to slower than anticipated growth, we have made changes to some of our sales leadership and we expect that we will see improvement by the end of the year.”

For the third quarter of 2015, the company reported net income applicable to common shares of $2.7 million and net income per fully diluted common share of $0.05, based on 58.9 million fully diluted shares outstanding, compared to net income applicable to common shares of $1.2 million and net income per fully diluted common share of $0.02 for the third quarter of 2014, based on 57.5 million fully diluted shares outstanding.

Adjusted earnings before interest, taxes, depreciation and amortization (adjusted EBITDA), as detailed in the reconciliation provided later in this release, was $10.7 million for the third quarter of 2015 (16 percent of third quarter 2015 revenues) compared to $8.2 million for the third quarter of 2014 (13 percent of third quarter 2014 revenues).

Fiscal 2015 and Fourth Quarter Outlook

Based on results from the first three quarters of the year, the company is lowering its full year revenue guidance for 2015. The company now expects full year revenues for 2015 to be between $274 million and $275 million, as compared to prior guidance of between $282 million and $286 million. The company now expects full year net income per fully diluted common share to be approximately $0.19 based on 58.8 million fully diluted common shares outstanding, as compared to prior guidance of $0.20 to $0.23.

For the fourth quarter of 2015, the company expects revenues to be between $68 million and $69 million and net income per fully diluted common share to be approximately $0.05, based on 59 million fully diluted shares outstanding.

“Despite a challenging third quarter, we are committed to our long term plan,” Hutchison said. “We will continue to focus on our base biologics business, our hardware business and our focused products. While the recent changes in sales leadership will take some time to gain traction, we believe we have put the pieces in place to achieve our goals.”

Conference Call

RTI will host a conference call and simultaneous audio webcast to discuss the third quarter results at 8:30 a.m. ET today. The conference call can be accessed by dialing (877) 383-7419. The webcast can be accessed through the investor section of RTI’s website at www.rtix.com. A replay of the conference call will be available on the RTI website following the call.

About RTI Surgical Inc.

RTI Surgical is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to delivering a higher standard, RTI’s implants are used in sports medicine, general surgery, spine, orthopedic, trauma and cardiothoracic procedures and are distributed in nearly 50 countries. RTI is headquartered in Alachua, Fla., and has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, please visit www.rtix.com.

Forward-Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management's beliefs and certain assumptions made by our management. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory actions or approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company's SEC filings may be obtained by contacting the company or the SEC or by visiting RTI's website at www.rtix.com or the SEC's website at www.sec.gov.

RTI SURGICAL, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(Unaudited, in thousands, except share and per share data)

For the Three Months Ended

For the Nine Months Ended

September 30,

September 30,

2015

2014

2015

2014

Revenues

$

66,529

$

65,163

$

206,172

$

191,937

Costs of processing and distribution

31,296

30,470

96,737

95,992

Gross profit

35,233

34,693

109,435

95,945

Expenses:

Marketing, general and administrative

25,464

26,863

80,088

80,019

Research and development

3,793

4,224

11,492

11,398

Total operating expenses

29,257

31,087

91,580

91,417

Operating income

5,976

3,606

17,855

4,528

Total other expense - net

(405

)

(296

)

(986

)

(1,136

)

Income before income tax provision

5,571

3,310

16,869

3,392

Income tax provision

(2,069

)

(1,324

)

(6,120

)

(1,355

)

Net income

3,502

1,986

10,749

2,037

Convertible preferred dividend

(832

)

(784

)

(2,460

)

(2,318

)

Net income (loss) applicable to common shares

$

2,670

$

1,202

$

8,289

$

(281

)

Net income (loss) per common share - basic

$

0.05

$

0.02

$

0.14

$

(0.00

)

Net income (loss) per common share - diluted

$

0.05

$

0.02

$

0.14

$

(0.00

)

Weighted average shares outstanding - basic

57,701,810

56,864,161

57,492,606

56,677,773

Weighted average shares outstanding - diluted

58,922,423

57,480,592

58,591,303

56,677,773

RTI SURGICAL, INC. AND SUBSIDIARIES

Reconciliation of Net Income (Loss) Applicable to Commons Shares to Adjusted EBITDA

(Unaudited, in thousands)

For the Three Months

For the Nine Months

Ended September 30,

Ended September 30,

2015

2014

2015

2014

Net income (loss)

$

2,670

$

1,202

$

8,289

$

(281

)

Interest expense, net

336

277

978

1,047

Provision for income taxes

2,069

1,324

6,120

1,355

Depreciation

3,011

2,830

9,212

8,104

Amortization of intangible assets

1,100

1,056

3,245

3,309

EBITDA

9,186

6,689

27,844

13,534

Reconciling items for Adjusted EBITDA

Preferred dividend

832

784

2,460

2,318

Non-cash stock based compensation

662

672

1,915

1,695

FX (gain) loss

69

19

8

89

Other reconciling items

Inventory purchase accounting adjustment (1)

-

-

-

5,708

Adjusted EBITDA

$

10,749

$

8,164

$

32,227

$

23,344

Adjusted EBITDA as a percent of revenues

16

%

13

%

16

%

12

%

Use of Non-GAAP Financial Measures

To supplement the Company’s condensed consolidated financial statements presented on a GAAP basis, the Company discloses adjusted EBITDA, a non-GAAP financial measure that excludes certain amounts. This non-GAAP financial measure is not in accordance with, or an alternative for, generally accepted accounting principles in the United States. A reconciliation of the non-GAAP financial measure to the corresponding GAAP measure is included in the table above.

The following is an explanation of the adjustment that management excluded as part of adjusted measures for the nine month period ended September 30, 2014 as well as the reason for excluding the individual item:

(1) 2014 Inventory purchase accounting adjustment – This adjustment represents the purchase price effects on the sale of inventory acquired in the Pioneer Surgical Technologies, Inc. acquisition in 2013, which have been included in costs of processing and distribution. Management removes the amount of these nonrecurring costs from the Company’s operating results to assist in assessing its operating performance in the periods affected and to supplement a comparison to the Company’s past operating performance.

Material Limitations Associated with the Use of Non-GAAP Financial Measures

Adjusted EBITDA should not be considered in isolation, or as a replacement for GAAP measures.

Usefulness of Non-GAAP Financial Measures to Investors

The Company believes that presenting adjusted EBITDA in addition to the related GAAP measures provide investors greater transparency to the information used by management in its financial decision-making which excludes the inventory purchase accounting adjustment. The Company further believes that providing this information better enables the Company’s investors to understand the Company’s overall core performance and to evaluate the methodology used by management to assess and measure such performance.